

## **Gambro BCT strengthens relationship with Pall to ensure leukoreduction leadership**

Stockholm, Sweden, November 29, 2000 - Gambro AB (OM Stockholm Exchange: GAMBaST, GAMBbST), a leading international medical technology and healthcare company, today announced that Gambro BCT, a leader in automated blood component collection, has entered into an exclusive purchasing relationship with the Pall Corporation (NYSE:PLL) to offer Pall's advanced leukoreduction technology to its customers.

Pall Corporation is a worldwide leader in filtration, separations, and purifications, offering proven and effective filters for leukoreduction.

Previously, the companies were in litigation regarding a patent dispute. This has been effectively resolved with the formation of the relationship.

David Perez, President of Gambro BCT, remarked, "We are delighted that we have resolved our differences and will now be able to offer Pall's advanced RBC filter technology with our products."

Pall Corporation's Medical business President Sam Wortham commented, "We are looking forward to working more closely with Gambro BCT, a world leader in automated blood component collection to support the needs of the blood banking community."

Pall currently supplies Gambro BCT with solutions necessary for blood storage as well as other components. Under this new arrangement Gambro BCT will purchase additional components from Pall, thus building and strengthening the relationship.

The primary business area for Gambro BCT is blood bank technology, which includes products and services that enable blood centers to collect, purify, and store blood components. This includes products for automatic collection, apheresis technology, and methods for reducing white blood cells from blood products.

*Gambro is a global medical technology and healthcare company with leading positions in renal care - services and products - and blood component technology. Gambro Healthcare is one of the leading providers of kidney dialysis services in the world with about 47,000 patients in 600 clinics worldwide. Gambro Renal Products comprises dialyzers, dialysis machines, blood lines and dialysis concentrates. Gambro BCT includes products for the separation and handling of blood components. The group, with revenue of approximately SEK 20 billion (USD 2.2 billion), has approximately 18,000 employees in some 40 countries.*

**Gambro AB**

A public company (publ)  
Reg no. 556041-8005  
Hamngatan 2, P O Box 7373  
SE-103 91 Stockholm  
Sweden  
Tel +46 8-613 65 00  
Fax +46 8-611 28 30  
info@gambro.com  
www.gambro.com

Pall Corporation has been an acknowledged technology leader in the increasingly complex and demanding filtration industry for more than 50 years. Pall serves customers throughout the healthcare and industrial marketplace.

For more information on the new relationship between Gambro BCT and Pall Corporation, contact David Perez, President, Gambro BCT, at +1-303-205 2475

For more information on Gambro, contact:

Bengt Mod  r, Corporate Communications, Gambro AB, tel. +46-70-513 65 33

Karin Avasalu, Corporate Communications, Gambro AB, tel. +46-8-613 65 00, +46-8-513 65 99

*Gambro is a global medical technology and healthcare company with leading positions in renal care - services and products - and blood component technology. Gambro Healthcare is one of the leading providers of kidney dialysis services in the world with about 47,000 patients in 600 clinics worldwide. Gambro Renal Products comprises dialyzers, dialysis machines, blood lines and dialysis concentrates. Gambro BCT includes products for the separation and handling of blood components. The group, with revenue of approximately SEK 20 billion (USD 2.2 billion), has approximately 18,000 employees in some 40 countries.*

**Gambro AB**

A public company (publ)  
Reg no. 556041-8005  
Hamngatan 2, P O Box 7373  
SE-103 91 Stockholm  
Sweden  
Tel +46 8-613 65 00  
Fax +46 8-611 28 30  
info@gambro.com  
www.gambro.com